We have been studying the biological role of reactive oxygen species (ROS) in the human cells. Specifically, we discovered that one of the natural antioxidant enzymes named Peroxiredoxin (Prx or PRDX) is a novel modulator of receptor signaling through controlling level of second messenger H₂O₂, and it is either inactivated by PTMs or silenced transcriptionally in the occluded arterial vessels, cancer cells, and brain regions with Alzheimer’s and Parkinson’s diseases. At the same time, we also discovered interesting natural compounds that mimic the catalytic activity of Peroxiredoxin enzyme. Using synthetic Prx mimics, we began to develop the therapeutics to cure chronic inflammatory diseases.   

Cardiovascular disease is top-ranked in terms of mortality among various chronic human diseases. Acute coronary syndrome and pulmonary arterial hypertension are typically caused by occlusion of arterial vessels. Opening and normalization of arterial vessel can be achieved by inhibition of smooth muscle hyperplasia as well as recovery of endothelium. Since we have identified novel redox-dependent receptor Tyr kinase (RTK) signaling in the arterial vasculature, our drug candidates modulating redox signaling provide the solution to cure the diseased artery. 

All members of VasThera are passionate researchers with the spirit of challenge and innovation. Putting our enthusiasm together, we do the best to develop innovative drugs that treat chronic diseases destroying the quality of human life.

Thank you.

Sang Won Kang, PhD.Chief Executive Officer, VasThera Co., Ltd.